monoclonal antibodies GD2

Phase 3Small molecule

FFederal Research Institute of Pediatric Hematology, Oncology and Immunology

monoclonal antibodies GD2 is one of 55 small molecule programs targeting Neuroblastoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroblastomaRecruiting

NeuroblastomaPhase 3

Recruiting

Competition

Competitive Landscape

88 competitors in Neuroblastoma

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

52 2

Vepesid

AAvyxa

Phase 3

40 3

Paraplatin

AAvyxa

Phase 3

35 4

Leukine

Sanofi

Phase 3

15 5

Camptosar

Pfizer

Phase 3

12 6

Tepadina

Jazz Pharmaceuticals

Phase 3

11 7

Alkeran

AApotex Inc.

Phase 3

28 8

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

26 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Neuroblastoma

NCT06071897

Clinical

Trials by Indication[1]

Neuroblastoma1 trial

Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma

Recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 3·NCT06071897·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for monoclonal antibodies GD2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — monoclonal antibodies GD2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for monoclonal antibodies GD2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal Research Institute of Pediatric Hematology, Oncology and Immunology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFederal Research Institute of Pediatric Hematology, Oncology and Immunology

monoclonal antibodies GD2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News